CancerConsultants.com Changes Name and Focus

CancerConsultants.com is changing its name and expanding the resources it provides to cancer patients and their families. They have launched a new website for cancer patients; www.CancerConnect.com that will allow people with cancer and those who care for them to share information, inspiration, hope, and support. www.CancerConnect.com combines www.CancerConsultants.com, a best-of-class content and news Web site for cancer patients with an online community that will allow cancer patients and their caregivers the ability to communicate with each other in a confidential and secure environment.

Visitors to www.CancerConnect.com will have access to comprehensive, current information on all aspects of the management of cancer and the added value of connecting with other patients who share their specific disease, such as breast, colon, prostate, and lung cancer. They can also participate in communities with broader concerns like nutrition and spirituality. Visitors to www.CancerConnect.com can access information and ask questions, share experiences, and connect with others who share their issues - all at a single destination.

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap